Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 12%
Buy 18%
Hold 65%
Sell 6%
Strong Sell 0%

Bulls say

Amgen is a leader in the biotechnology industry with a strong portfolio of flagship drugs and a growing pipeline of new products. The company's recent quarterly performance beat expectations and shows a solid trend in prescription sales for multiple growth drivers. While there are some challenges ahead with upcoming patent expiries, Amgen's strong base business and ongoing business development initiatives provide stability. Investors are eagerly awaiting data releases for potential growth drivers, including the weight loss drug MariTide and the cardiovascular drug olpasiran. However, these drugs are not expected to reach the market within the next 12 months, and key phase III readouts for the oncology pipeline and I&I franchise are not expected until 2027/2028.

Bears say

Amgen is facing structural headwinds from the loss of exclusivity across key product franchises, leading to a decrease in revenue estimates and a slight decrease in the DCF-derived price target to $340. Additionally, the company's emerging products, such as Tepezza and Uplizna, offer potential long-term growth drivers but are largely unproven, creating uncertainty. While there are upside risks, such as strong data from pipeline assets and better-than-expected product performance, there are also downside risks, such as disappointing pipeline data and increased regulatory or pricing concerns. Therefore, the current risk/reward profile for Amgen is largely balanced, with limited visibility into its potential to offset revenue erosion pressures and sustain long-term growth.

Amgen (AMGN) has been analyzed by 17 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 18% recommend Buy, 65% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 17 analysts, Amgen (AMGN) has a Hold consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $356.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $356.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.